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RESUMO 
A angiogénese consiste na formação de novos vasos sanguíneos através de 
vasos pré-existentes. Nos adultos, a vasculatura mantêm-se quiescente, excepto em 
processos altamente controlados, como nos ciclos reprodutores femininos e na 
cicatrização. No entanto, muitas doenças evoluem graças à angiogénese, como a 
artrite reumatóide, a neovascularização ocular, o crescimento tumoral e a 
metastização. Em tumores, a angiogénese é induzida sobretudo pelas condições de 
hipóxia que ocorrem nestes tecidos, levando à produção de vários factores pró-
angiogénicos como o VEGF (o mais importante), PDGF, FGF, angiopoitinas, entre 
outros. O VEGF pode sofrer “splicing” alternativo, levando à expressão de quatro 
isoformas que variam no número de aminoácidos e na presença ou ausência de locais 
de ligação à heparina. VEGF165, VEGF189 e VEGF206 podem ligar-se às membranas 
celulares ou à matriz extracelular (MEC) através dos domínios de ligação à heparina; o 
VEGF121 é uma proteína não ligada à heparina, apresentando-se numa forma solúvel, 
livremente difusível no meio. Para além destes factores pró-angiogénicos, as 
metaloproteases de matriz (MMPs) também são importantes na degradação da 
membrana basal que envolve os vasos, permitindo a migração das novas células 
endoteliais. A angiogénese é importante na progressão de uma patologia crónica para 
uma aguda, mais agressiva, estando bastante estudada em tumores sólidos, sendo, 
inclusivamente, um dos principais alvos terapêuticos nestas doenças. No entanto, só 
mais recentemente se começou a atribuir importância a este processo em tumores 
hematológicos, que ocorrem na medula óssea (MO) e órgãos linfáticos.  
As disfunções da MO são doenças clonais resultantes da transformação 
neoplásica de células estaminais/progenitoras hematopoiéticas (CEPH). Entre elas, a 
leucemia mielóide aguda (LMA) é caracterizada por um rápido aumento de células 
sanguíneas imaturas, os blastos, devido a uma inibição nas vias apoptóticas destas 
células. Tal interfere com a homeostasia da MO e inibe a produção normal de células 
sanguíneas. As síndromes mielodisplásicas (SMD) são um conjunto heterogéneo de 
doenças hematológicas que apresentam frequentemente citopénias no sangue 
periférico, apesar de a MO poder apresentar-se  normocelular ou hipercelular. Esta 
situação pode estar relacionado com um aumento  da apoptose que se verifica  numa  
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RESUMO 
ou em várias linhagens hematopoiéticas. As SMD apresentam um risco elevado de 
progredir para LMA. Apesar das causas genéticas destas doenças estarem bem 
descritas, sabe-se que determinados componentes do microambiente medular 
protegem as células malignas da quimioterapia e propiciam a sua proliferação e 
sobrevivência. No entanto, muito falta saber acerca do microambiente na progressão, 
ou mesmo iniciação, das doenças hematológicas, nomeadamente na angiogénese que 
lhes poderá estar associada. Foi reportado um aumento da angiogénese em SMD e 
LMA, comparativamente a dadores saudáveis, o que sugere um papel deste processo 
nestas doenças. O microambiente da MO inclui o estroma (fibroblastos, células 
endoteliais, osteoblastos, macrófagos), factores solúveis (factores de crescimento, 
citocinas e quimiocinas), MMPs e a MEC. A MEC inclui várias moléculas como a 
fibronectina (FN), lamininas, colagéneos, glicosaminoglicanos e proteoglicanos, sendo 
uma estrutura bastante dinâmica com uma composição espacial e temporal bem 
definidas dentro da MO, o que influencia as propriedades das CEPH. A FN, as MMPs e 
vários factores de crescimento estão alterados quantitativamente em diversos 
tumores sólidos.  
Assim, o objectivo deste trabalho foi compreender se o microambiente da MO 
é diferente entre SMD e LMA e que papel este factor poderá ter na progressão destas 
doenças. Através da técnica de imunoprecipitação, verificámos um aumento 
significativo de VEGF ligado à FN em MO de doentes com LMA. Por outro lado, a 
análise por ELISA do sobrenadante de MO revelou um aumento de VEGF solúvel na 
MO de doentes com SMD. Nesta doença, observámos um aumento da actividade das 
MMPs comparativamente aos doentes com LMA, que poderá ser responsável pela 
libertação do VEGF solúvel nas MO de SMD e, consequentemente, ao aumento da 
angiogénese verificado nesta patologia. As nossas experiências in vitro comprovaram 
que quando as MMPs são inibidas, há uma diminuição do VEGF solúvel. Estes 
resultados sugerem que a biodisponibilidade de factores angiogénicos, 
nomeadamento do VEGF, pode ser controlada pelo seu grau de associação à FN 
(dependende das MMPs) e que este fenómeno é importante na angiogénese das 
doenças hematológicas. Por imunohistoquímica,  observámos um aumento da FN em  
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RESUMO 
MO de doentes com LMA e quisemos saber o que poderia estar a regular a expressão 
desta proteína. Sabe-se que a via de sinalização Notch, é importante na angiogénese 
de tumores sólidos, mas o seu papel nas doenças hematológicas é bastante 
controverso. Um estudo em embriões de ratinho demonstrou que a sobrexpressão do 
receptor Notch leva a um aumento da FN à volta dos vasos sanguíneos em formação. 
Por PCR quantitativo realizado nas nossas amostras de MO, concluímos que esta via de 
sinalização está activa em ambas as doenças. No entanto, observámos uma forte 
correlação entre a expressão de elementos da via NOTCH e a expressão da FN em MO 
com LMA, o mesmo não se tendo verificado para as SMD. Aliando estes resultados aos 
anteriores relativos à regulação do VEGF, concluímos que em LMA, o VEGF encontra-se 
essencialmente ligado à FN, sendo a actividade das MMPs inferior à encontrada na MO 
com SMD. Nestas condições, a biodisponibilidade do VEGF é mais regulada, tornando a 
angiogénese menos exuberante. Além disso, a via de sinalização Notch poderá estar a 
regular a produção/deposição de FN que envolve os novos vasos sanguíneos, 
contribuindo para a formação de vasos mais estáveis e funcionais. Por outro lado, em 
SMD, a elevada actividade das MMPs leva a um aumento do VEGF solúvel na MO que, 
aliado a uma diminuição da FN à volta dos vasos sanguíneos em formação 
(dependente da via de sinalização Notch), contribui para um aumento da angiogénese 
e formação de vasos instáveis e menos funcionais. Assim, as diferenças encontradas no 
microambiente medular de SMD e LMA, nomeadamente os diferentes níveis de VEGF, 
MMPs e FN, deverão condicionar a angiogénese nestas doenças e, provavelmente, 
algumas das suas características patológicas: aumento da apoptose em SMD e 
sobrevivência dos blastos em LMA. Dentro do nosso conhecimento, nada foi descrito 
sobre a regulação da biodisponibilidade do VEGF na MO em disfunções hematológicas, 
assim como sobre a sinalização Notch na angiogénese destas doenças. 
 
Palavras-chave: Medula óssea, microambiente, angiogénese, síndromes 
mielodisplásicas, leucemia mielóide aguda, fibronectina, VEGF, metaloproteases de 
matriz 
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ABSTRACT 
Bone marrow (BM) malignancies are clonal disorders resulting from neoplastic 
transformation of hematopoietic stem/progenitor cells (HSPCs). Among them, acute 
myeloid leukemia (AML) is characterized by a rapid increase in immature blood cells 
numbers, due to apoptosis suppression; myelodysplastic syndromes (MDS) are 
characterized by peripheral cytopenia, related with increased apoptosis, and can 
develop to AML.  Angiogenesis is an important event that mediates the progression 
from a chronic to a more acute and aggressive pathology, and its significance in 
hematological malignancies has just beginning to be explored. BM microenvironment, 
including soluble factors and extracellular matrix (ECM), in particular fibronectin (FN) 
that has been found increased in solid tumors, may be responsible for BM disease 
progression, but its precise role in this context has been poorly investigated. Thus, the 
aim of this thesis was to know if the BM microenvironment differs between MDS and 
AML and what role might such factor be playing in disease progression. Our results 
indicate that MDS BM has more soluble VEGF, a pro-angiogenic factor, and higher 
matrix metalloproteinases (MMPs) activity, which may be responsible for increased 
angiogenesis occurring in this disease. Notch pathway, known to be involved in solid 
tumors angiogenesis, does not regulate FN expression in MDS BM, which leads to new 
formed vessels instability. In AML, VEGF is kept majorly bounded to FN, and MMPs 
activity is lower than in MDS BM. In such conditions, VEGF bioavailability is more 
regulated, being angiogenesis less exuberant. In addition to this, Notch pathway 
regulates FN deposition around new vessels, contributing to the formation of a more 
functional and stable vasculature in AML. To our knowledge, nothing has been 
described about the regulation of VEGF bioavailability in BM diseases, as well as 
regarding the possible effect of Notch signaling in angiogenesis of hematological 
dysfunctions.  
 
Keywords: Bone marrow, microenvironment, angiogenesis, myelodysplastic 
syndromes, acute myeloid leukemia, fibronectin, VEGF, matrix metalloproteinases 
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INTRODUCTION 
 Angiogenesis: key players and biological importance 
Blood vessels are fundamentally composed of endothelial cells, which 
interconnect to form the tubes that direct and maintain blood flow and tissue 
perfusion. The development of blood vessels in embryogenesis occurs by two 
processes: vasculogenesis, whereby endothelial cells derive primarily from progenitor 
cells, and angiogenesis, in which new capillaries sprout from existing vessels. In adult 
mammals, new vessels are produced only through angiogenesis although a role for 
endothelial progenitors has been shown in several physiological and pathological 
situations. 
In adults, the vasculature is quiescent except for highly organized processes in 
the female reproductive cycles (ovulation, menstruation, implantation, pregnancy) 
(Hanahan and Folkman, 1996). However, many diseases are driven by persistent 
unregulated angiogenesis, like rheumatoid arthritis (Moon et al., 2010), ocular 
neovascularization, tumor growth and metastasis (Hanahan and Folkman, 1996; 
Parangi et al., 1996), among others (reviewed in Carmeliet, 2005).  
Major growth factors involved in the angiogenic process 
  The formation of new blood vessels and their permeability is primarily 
regulated by vascular endothelial growth factor (VEGF) or VEGF-A (after the discovery 
of other VEGF family members, like VEGF-B, -C, -D and -E) (Connolly et al., 1989; 
Ferrara and Henzel, 1989). VEGF is a dimer composed by two subunits that vary 18 to 
34kDa subunits (Connolly et al., 1989). Four different transcripts of this protein have 
been identified resulting from alternate splicing of exon 6 and 7, which alters their 
heparin-binding affinity, and amino acid number: originating four isoforms, 206, 189, 
165 and 121 (Tischer et al., 1991). In addition, inclusion or exclusion of exons 6 and 7 
mediate interactions with heparan sulfate proteoglycans (HSPGs) and neuropilin (NRP) 
co-receptors on the cell surface, enhancing their ability to bind and activate the VEGF 
receptors (VEGFR). This molecule had specific mitogenic effect on vascular endothelial 
cells, but not in adrenal cortex cells, lens epithelial cells, corneal endothelial cells, 
keratinocytes or fibroblasts (Ferrara and Henzel, 1989). Recently, a novel group of iso- 
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forms, the so-called “b-isoforms” or “VEGFxxxb” isoforms, have been described. These 
transcripts of the VEGF-A gene code for polypeptides with the same length as the 
classical ones, because exon 8 (present in all the formerly known isoforms) is 
substituted by an alternatively spliced exon of the same size (exon 8b) (Ladomery et 
al., 2007; Catena et al., 2010). 
 VEGF acts via two receptors protein tyrosine kinases, flt-1 (fms-like tyrosine 
kinase, VEGFR1) or flk-1 (fetal liver kinase-1; KDR, VEGFR2) (de Vries et al., 1992; Quinn 
et al., 1993). The binding of VEGF to VEGFR, in particular to flk-1/KDR, is responsible 
for activating several signaling cascades in endothelial cells, within different 
physiological functions, including survival (Gerber et al., 1998), proliferation (Thakker 
et al., 1999), and vascular permeability (Gille et al., 2001). Moreover, VEGF can also 
bind to NRP-1, acting as a co-receptor for flk-1/KDR, and enhancing the VEGF signaling 
(Herzog et al., 2011). 
Platelet-derived growth factor (PDGF) is a family of heterodimeric or 
homodimeric isoforms of A- and B- polypeptide chains, synthesized as precursor 
molecules undergoing proteolytic maturation. These molecules are produced by 
different cell types and act via protein kinase receptors (Heldin and Westermark, 
1999). PDGF family has a complex role in regulation of blood vessel formation (Cao et 
al., 2002).   
Fibroblast growth factors (FGFs) are a family of 20 heparin-binding growth 
factors. FGFs exert their pro-angiogenic activity by interacting with various endothelial 
cell surface receptors, including tyrosine kinase receptors, HSPGs, and integrins (Kan et 
al., 1993). The binding of FGF isoforms to heparin sites protect growth factors from 
acid, heat and degradation by circulating proteases, as thrombin (FGF-1), trypsin (FGF-
2) or plasmin, affecting biological signaling (Powers et al., 2000). Several isoforms of 
this family are mitogenic for endothelial cells, like FGF-4 (Delli-Bovi et al., 1988), but 
they have pleiotropic effects, stimulating the growth of several other cells, as smooth 
muscle cells, fibroblasts, and certain epithelial cells (Folkman and Shing, 1992). 
Furthermore, FGFRs have variable activity in promoting angiogenesis, with FGFR-1 sub- 
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group being associated with tumor progression and FGFR-2 subgroup with either early 
tumor development or decreased tumor progression (reviewed in Korc, 2009). 
The angiopoietin (Ang) family of growth factors is also important for blood 
vessel formation (Valenzuela et al., 1999). Ang-1 and Ang-4 are angiogenic factors that 
signal through the Tie-2 receptor tyrosine kinase, essential for normal vascular 
development in the mouse (reviewed in Peters et al., 2004; Fukuhara et al., 2009, 
2010). On the other hand, Ang-2 and Ang-4 bind to Tie-2 receptor and act as 
antagonists of Ang1, what is unusual for a family of ligands (Maisonpierre et al., 1997). 
The biological action of angiopoietin family depends on the unique mixture of 
angiogenic factors and their receptors operating in tissue microenvironment (Olsen et 
al., 2006). 
Proteolytic degradation of the extracellular matrix: also part of the angiogenesis 
processes and the remodeling of tissues 
Proteolytic degradation of extracellular matrix (ECM) is implicated in many 
steps of the angiogenic cascade, not only by degradation of vessel basement 
membranes, but also in cell migration, ECM invasion and capillary morphogenesis 
(Maciag et al., 1982; Bellon et al., 2004; reviewed in Bourboulia and Stetler-Stevenson, 
2010). ECM proteolysis results from secretion and activation of matrix 
metalloproteinases (MMPs) in response to exogenous signals, such as cytokines, 
growth factors and cell-matrix interactions (Bellon et al., 2004). MMP-9 is upregulated 
during the carcinogenic process in pancreatic islets, having an effect on the switch 
from vascular quiescence to angiogenesis. It mobilizes VEGF stored in ECM, leaving it 
available to its receptor (Bergers et al., 2000). Suppression of MMP-2 reduced 
angiogenesis, inhibiting the transition from the pre-vascular to the vascular stage of 
tumor development in a chondrosarcoma model (Fang et al., 2000). Moreover, several 
endogenous molecules are produced by partial proteolysis of ECM such as angiostatin 
derived from plasminogen, endostatin from collagen XVIII, anastellin from fibronectin 
(FN) and many others. All these molecules have pro- and anti-angiogenic activities 
(reviewed in Heissig et al., 2003; Bellon et al., 2004; Rundhaug, 2005; Milkiewicz et al., 
2006).  
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Metabolic changes underlying the angiogenic process: hypoxia as an example 
Hypoxia is accepted as one of the basic mechanism that initiates and regulates 
angiogenesis in tumors. It mediates the up-regulation of pro-angiogenic factors, like 
VEGF, and the downregulation of anti-angiogenic factors (Messmer-Blust et al., 2009), 
leading to blood vessel growth and, eventually, metastasis.  The hypoxia-inducible 
factor 1alpha (HIF1α) is activated under hypoxia conditions and, in a glioma model, it 
stimulated the recruitment of CD45+ BM-derived cells to tumor areas.  These cells 
produce MMP-9 that is essential to initiate the angiogenic switch and also regulates 
tumor invasiveness (Du et al., 2008). Also under hypoxia, the membrane type-2 MMP 
(MT2-MMP) is upregulated in pancreatic cancer cells, non-small cell lung cancer cells 
and cervix cancer, cells and this could confer resistance to hypoxia-induced apoptosis 
and increase invasiveness of cancer cells (Zhu et al., 2011). 
Clinical relevance for angiogenesis: possible therapeutic targets 
Given the biological relevance attributed to angiogenesis, in tumors but also in 
other diseases, soon clinical researchers began to attempt at targeting this complex 
process for therapeutic purposes. The inhibition of VEGF–VEGFR interactions shows a 
significant improved survival and disease-free survival in patients with cancer, 
decreasing tumor growth. However, in several cancers, this inhibition is less effective 
because patients acquire resistance during treatment or originally the tumor is less 
sensitive to VEGF signaling. Alternatively, drugs against targets related to VEGF-
independent regulation of angiogenesis could be good candidates to treat these 
patients. This may include several molecules, such as angiostatin and endostatin that 
were reported to be natural anti-angiogenic proteins in the body (Matter, 2001; 
Shibuya, 2008). Recent studies have shown that FGFs can act synergistically with VEGF 
to amplify tumor angiogenesis, highlighting that targeting of both the FGF and VEGF 
pathways may be more efficient in suppressing tumor growth and angiogenesis than 
targeting either factor alone (reviewed in Korc, 2009). Even though the importance of 
angiogenesis was first shown in setting of solid cancer progression many years ago 
(Folkman, 1971), it has also been associated with hematological diseases (Perez- 
Atayde et al., 1997; Aguayo et al., 1999).  VEGF and basic  FGFs expression on hemato- 
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poietic organs (bone marrow (BM) and lymphatic organs) define some clinical 
characteristics in leukemias and non-Hodgkin’s lymphoma, and their levels in 
serum/plasma patients are predictors of poor prognosis (Fiedler et al., 1997; Perez-
Atayde et al., 1997; Aguayo et al., 2000; De Bont et al., 2001; Fragoso et al., 2007; 
reviewed in Albitar, 2001; Moehler et al., 2003).  
In hematological tumors, MMPs expression has been shown to be upregulated 
in some leukemia, lymphomas and multiple myeloma (Barillé et al., 1997; Kossakowska 
et al., 1999; Kuittinen et al., 2001; 2003; Pennanen et al., 2008). Similar to solid tumor, 
in hematological tumors the BM microenvironment (stroma cells, ECM and soluble 
factors) must play a role in the angiogenic switch, but its actual importance on this 
process is not completely understood. Litwin and colleagues, comparing the low 
angiogenic potential of acute myeloid leukemia (AML) blasts in vitro with the high 
vessel density in BM patients in vivo, concluded that angiogenesis in AML likely 
represents a response to microenvironmental factors in vivo, rather than being an 
intrinsic property of leukemic cells (Litwin et al., 2002). It is, thus, important to 
understand how angiogenic factor bioavailability, in particular of VEGF, can be 
modulated by the BM microenvironment, which can help improving anti-angiogenic 
therapies in hematological diseases.  
 
BM microenvironment in hematopoiesis: creating niches for hematopoietic stem 
cells 
The BM is the major hematopoietic organ in adult and it is found in the interior 
of long (e.g. humerus, femur, tibia, fibula) and flat bones (e.g. ribs, vertebrae, cranium, 
hip). It is a trabecular structure irrigated by large vessels and sinusoids, and filled with 
stromal and hematopoietic cells.  
BM microenvironment comprises stromal cells (as osteoblasts, adypocytes, 
endothelial cells, fibroblasts, macrophages), soluble factors (growth factors, cytokines 
and chemokines) produced by stromal and hematopoietic cells (HCs), and the ECM. 
Within BM microenvironment, two well defined regions called niches were considered  
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to provide hematopoietic stem/progenitor cells (HSPCs) with critical instructions to 
self-renew, proliferate, differentiate, homing, migrate and survival (reviewed in Li and 
Xie, 2005; Kacena et al., 2006; Moore and Lemischka, 2006; Wilson and Trumpp, 2006; 
Yin and Li, 2006; Arai and Suda, 2005; Scadden, 2007). HSPCs are believed to be 
located near bone surfaces (the osteoblastic niche) or associated with the sinusoidal 
endothelium (the vascular niche); the molecular signals generated by these two niches 
have been extensively studied (in particular for the osteoblastic niche). Osteoblasts 
produce important signaling molecules like osteopontin and Ang that interact with 
their receptors on HSPCs, keeping these cells in a quiescent state (Grassinger et al., 
2009; reviewed in Arai and Suda, 2007; Suda et al., 2005). On the other hand, the 
vascular niche is considered to promote proliferation and further differentiation of 
HSPCs (Kopp et al., 2005); it produces FGF-4 and chemokines such as stromal derived 
factor (SDF-1) (reviewed in Yin and Li, 2006) that recruits the HSPCs from the 
osteoblastic to vascular niche. Recently, with new imaging approaches, it is becoming 
evident that endosteal and vascular compartments may not be mutually exclusive in 
terms of their role on HSPC fate (Kiel and Morrison, 2008).  
ECM in the BM microenvironment 
The ECM component of the BM can be seen as a very dynamic structure, which 
spatial and temporal composition within BM creates niches that highly influence the 
HSPCs proprieties (Figure 1). These niches also function as a soluble factors reservoir, 
controlling their availability to adjacent cells. To acquire proper information from the 
surrounding ECM, hematopoietic cells express adhesion molecules in a regulated 
fashion, being integrins and proteoglycans the major receptors for ECM (reviewed in 
Campbell and Humphries, 2011; Kim et al., 2011). Adhesion molecules participate in a 
range of signal transduction processes involving not only cell adhesion, but also 
migration, proliferation and apoptosis.  In more detail, the BM ECM is an intricate 
network of proteins (e.g. collagens), glycoproteins (FN, laminins) glycosaminoglycans 
(e.g. hyaluronan) and proteoglycans (e.g. syndecans) whose turnover is tightly 
controlled by the adjacent cells (reviewed in Kim et al., 2011).  ECM molecules are pro- 
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duced in response to diverse environmental stimuli which are intrinsic to organ 
function, or may be present in stress situations involving tissue turnover such as during 
wound healing processes, or in malignancy (reviewed in Hynes, 2009). Nevertheless, 
the contribution of ECM in regulating cell-tissue-organ function, namely its role in BM 
homeostasis, has received little attention, and the majority of studies have focused on 
their receptors integrins and the signaling pathways activated through them. Also, 
most of studies have been made in vitro. The effect of ECM in hematopoiesis varies 
accordingly to cell lineage and maturation stage of the progenitor cell (reviewed in 
Lam and Adams, 2010). In long-term (LT) BM cultures, progenitors that adhere to FN 
proliferate significantly less than non-adherent progenitors (Hurley and Verfaillie, 
1995). Collagen significantly increases the adhesion of human long term bone marrow 
(LTBM) cells and induces a decreased in myeloid progenitor cell production, whereas 
FN increases myelopoiesis (Hassan et al., 1997). Laminin-10/11 is highly adhesive to 
lineage-committed myelomonocytic and erythroid progenitor cells and several 
lymphoid and myeloid cell lines, whereas laminin-8 is less adhesive. Ex vivo culture of 
murine HSCs in the presence of FN and laminin resulted in expansion of primitive stem 
cells and improvement in the marrow engraftability (Sagar et al., 2006). Other ECM 
molecules seem to modulate HSPCs microenvironment.  Heparan sulphate is produced 
by stromal cells and it presents cytokines to HSPCs, as well as promoting their ligation 
to the ECM molecules like thrombospondin. This leads to the formation of discrete 
niches, thereby orchestrating the controlled growth and differentiation of stem cells 
(Coombe, 1996; Gupta et al., 1998). Tenascin is co-localized with other ECM molecules 
such as FN and collagen type III in the microenvironment surrounding the maturing 
hematopoietic cells and has a role in the retention of HSPCs in the stroma (Klein et al., 
1993). Osteopontin negatively regulates HSC numbers, as evidenced by increased of 
these cells in the osteopontin-null microenvironment (Calvi et al., 2003; Stier et al., 
2005). ECM is also essential in megakaryocyte (MK) differentiation. Depending on 
which integrin is expressed at their surfaces, these cells exhibit different affinities for 
ECM ligands, which in turn influence their fates (Zweegman et al., 2000; Inoue et al., 
2003; Balduini et al., 2008; Mazharian et al., 2011). Additionally, MKs are important 
producers of MMPs, being MMP-9 secretion essential for MK migration towards  blood 
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Figure 1: Schematic representation of major steps in hematopoiesis within BM 
microenvironment. The image represents BM niches: the osteoblastic niche, where quiescent 
HSPC localize, and the vascular niche, where HSPC differentiation occurs. Myeloid progenitor 
cells (MPC) originate basophils, neutrophils, eosinophils, monocytes, MKs (give rise to 
platelets), and erithrocytes, and lymphocyte progenitor cells (LPC) originate lymphocytes B and 
T, and natural killer cell (NK) cell. BM microenvironment is composed by ECM proteins 
(collagen), glycoproteins (FN and laminin) and glycosaminoglycans, soluble factors (e.g. growth 
factors, MMPs), and stroma (endothelial cells, osteoblasts, fibroblasts, macrophages, 
adipocytes).  
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vessels and posterior platelets release (Lane et al., 2000). MMPs production by MKs 
may also modulate BM niches in terms of ECM remodelling, and thus, the fate of 
hematopoietic cells. Cell adhesion events are also very important to assure the success 
of transplantation (Chute, 2006; Lam and Adams, 2010). Absence of β1-containing 
integrins (in particular, α4β1 integrin) resulted in sequestration of HSCs in the 
circulation and their reduced adhesion to endothelial cells (Hirsch et al., 1996; Arroyo 
et al., 1999; Dave et al., 2000; Potocnik et al., 2000; reviewed in Imai et al., 2010), 
impairing their entrance in BM. 
FN, a major constituent of ECMs, plays an important role during 
embryogenesis, wound healing and cancer invasion by promoting cell adhesion, 
motility, cell cycle progression and cell survival (Hynes and Yamada, 1982; Humphries, 
1989; Frisch and Ruoslahti, 1997). Reduction or loss of FN expression occur in many 
transformed cells in culture (Ruoslahti, 1989), but its overexpression is also associated 
with various human tumor cells like colorectal cancer, breast carcinoma, head and 
neck squamous carcinoma, and metastatic melanoma (Zhang G, 1997; Bittner et al., 
2000; Jiang et al., 2002; Al Moustafa, 2002). FN and their integrin receptors are also 
key regulators of endothelial growth (Hynes et al., 1999; Dvorak, 2005). While laminins 
and collagens appeared early in evolution, FN has been found only in vertebrates and 
its appearance in evolution correlates with the appearance of organisms with 
endothelial cell-lined vasculature (Hynes and Zhao, 2000; Whittaker et al., 2006; Astrof 
and Hynes, 2009). It is a high-molecular weight (440KDa) molecule, consisting of two 
nearly identical monomers linked by a pair of disulfide bonds. The FN protein is 
produced from a single gene, but alternative splicing of its pre-mRNA leads to the 
creation of several isoforms (Figure 2). There are two types of FN: the soluble plasma 
FN, a major protein  component of blood plasma (300μg/ml) and produced in the liver 
by hepatocytes, and the insoluble cellular FN, a major component of ECM (reviewed in 
Pankov and Yamada, 2002). Within BM, FN is localized in the osteoblastic niche, the 
region for which HSPCs have high affinity, but has also a wide distribution in central 
BM region (Nilsson et al., 1998). Its broad allocation suggests that FN may be 
important in creating specific niches for HCs, and some roles of this molecule in 
hematopoiesis have been revealed, mostly on in vitro studies (see above). 
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Figure 2. Schematic representation of human dimeric FN and its several binding domains. 
Each 220kDa FN monomere comprises multiple type I (green circles), type II (yellow lozenge) 
and type III (blue rectangle) repeats. Several FN isoforms can be obtained by alternative 
splicing: the entire EDA and EDB domains are independently included or excluded by exon 
skipping, whereas the IIICS domain undergoes complex splicing of mRNA transcribed from a 
single exon (exon subdivision is indicated). The binding sites for interaction between FN and 
collagen, fibrin, heparin, cells, and to other FN molecules are also represented. Cell-binding 
sites include the RGD domain (for α5β3 and αVβ3 integrin interaction) and the IIICS domain 
(for α4β1 integrin interaction).  
 
 Nevertheless, not too much is known about its importance in hematological 
diseases, in particular in the angiogenic processes associated with these malignancies. 
In this context, most of the studies only concern ECM remodeling by MMPs, but which 
factors regulate FN expression during this process are still to identify. Also in other 
biological systems, the regulation of FN has not been totally explored. Hepatocyte 
growth factor/scatter factor (HGF) induces FN expression and extracellular assembly 
on the surface of melanoma cells through activation of mitogen-activated protein 
(MAP) kinase pathway (Gaggioli et al., 2005). The pleiotropic cytokine transforming 
growth factor-β (TGF-β) is the well known regulator of FN, being studied in epithelial-
to-mesenchyme transition contexts, like in embryogenesis and in fibrosis (as an 
example, see Sureshbabu et al., 2011). A recent study on mouse embryonic angiogene- 
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sis revealed that overexpression of the Notch ligand Dll4 increases the deposition of FN 
around the vessels, although the direct role of Notch signaling on FN production has 
not been addressed (Trindade et al., 2008). In BM, nothing is known about the 
regulation of FN (or other ECM molecules) expression, or in homeostasis, or in disease. 
 
BM diseases: from BM dysfunctions to malignancy 
BM malignancies are clonal disorders resulting from neoplastic transformation 
of HSPCs. They include leukemias, lymphomas and multiple myeloma. Other related 
BM diseases, but not considered cancer forms, comprise myeloproliferative syndromes 
(MPS) and myelodisplastic syndromes (MDS). 
 Leukemias are classified accordingly to the hematopoietic cells which undergo 
the clonal transformation: lymphoblastic or lymphocytic leukemias – involving 
lymphocyte precursors - and myeloid or myelogenous leukemias – involving myeloid cell 
but also erythrocyte or platelet precursors. They are also subdivided in acute or chronic 
leukemias. Acute leukemias are characterized by a rapid increase in the numbers of 
immature blood cells, making the BM unable to produce healthy blood cells. It requires 
immediate treatment due to the rapid progression of the disease that leads to the exit 
of malignant cells into the bloodstream and spread to other organs of the body. Chronic 
leukemias are characterized by the excessive production of relatively mature, but still 
abnormal, leukocytes. Typically, they take years to progress, so they are sometimes 
monitored for some time before treatment to ensure maximum effectiveness of 
therapy. Combining these two classifications, four main types of leukemias emerge 
(although other forms of rare leukemias can occur): acute lymphoblastic leukemia (ALL), 
AML, chronic lymphocytic leukemia (CLL), and chronic myelogenous leukemia (CML) 
(Swerdlow et al., 2008). 
MPS are a group of BM clonal disorders in which excess cells are produced. They 
are categorized by the presence or absence of Philadelphia chromosome (t9;22) and 
include, among others primary or idiopatic myelofibrosis (PMF), polycythemia vera  (PV), 
 13 
 
INTRODUCTION 
essential thrombocythemia (ET) (Philadelphia chromosome-negative), and CML 
(Philadelphia chromosome-positive). CML can occur independently or progress from a 
PMF and is characterized by the presence of HSPC expressing the bcr-abl oncogene, 
with abnormal release of these clonal cells into the circulation. A complete genetic and 
clinicopathological classification of this group of disorders can be consulted, for 
instance, in Michiels et al., 2007; Tefferi and Gililland, 2007, 2006; Michiels and Thiele, 
2002.  
MDS are a heterogenous group of clonal hematopoietic diseases characterized 
by peripheral cytopenia (despite a normocellular or hypercellular BM) and with a 
variable probability to progress to AML (Miyazato et al., 2001; Braun et al., 2006; Nolte 
and Hofmann, 2008). The incidence of these conditions has risen sharply over the past 
several years, making them the most common malignant BM disorders. It has become 
apparent that the ineffective hematopoiesis is largely caused by excessive apoptosis of 
myeloid precursors (Braun et al., 2007; reviewed in Westwood and Mufti, 2003). 
Recent observations suggest that downregulation of α4β1 and α5β1 integrins on HSC, 
correlated with decreased in vitro adhesiveness to FN fragments, could be a newly 
identified proapoptotic mechanism in MDS (Delforge et al., 2005). Inversely, the 
evolution of MDS from early relatively chronic phenotype to an aggressive AML is 
accompanied by a suppression of apoptosis in the malignant cells, mediated by 
changes in intracellular levels of Bcl-2-family proteins (reviewed in Westwood and 
Mufti, 2003). MDS-associated AML (secondary AML) is rarely cured by conventional 
chemotherapy (reviewed in Hamblin, 1992), which contrasts with the somewhat better 
outcome of de novo AML. The protein Delta-like (Dll), distantly related to Delta-Notch 
family of signaling proteins, has highly selective expression in the individuals with MDS 
and lower in secondary AML, being absent from de novo AML. This makes Dll a good 
candidate molecule to differentiate MDS from AML (Miyazato et al., 2001).  
As biopsies from several MDS patients have been used on this project, a brief 
classification of this disease is given due to the heterogeneity of the samples. The 
French-American-British (FAB) group established the first classification of MDS in 1982, 
defining five subtypes based on morphology, the number of blasts (in BM and periphe- 
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ral blood) and monocyte counts. This classification reflects the progression and the 
clinical course of MDS but, although providing important diagnostic information, 
revealed some limitations. To overcome them, in 2001, the World Health Organization 
(WHO) classification suggested new subtypes of MDS (table 1) (Bennett et al., 1982).  
 
Table 1. MDS classification according to WHO 
 
 
However, this classification did not include important information on genetic 
abnormalities, a major prognostic factor in MDS patients. So, another classification 
based on significant prognostic factors, proposed in 1996 by the International 
Prognostic Scoring System (IPSS), defines four groups of risk (table 2).  
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Table 2. MDS Risk proposed by IPSS 
 
 
BM microenvironment in hematological diseases: the deregulation of stem cell 
niches 
Malignant hematopoietic cells are known to express particular cell adhesion 
repertoires that provide them with proliferative and survival advantages within the BM 
microenvironment. Specific niche composition provides ideal conditions for some 
leukemic cells to escape from chemotherapy-induced death and acquire drug-
resistance. There are several reviews on this subject (e.g. Verfaillie et al., 1997; Rizo et 
al., 2006; Konopleva et al., 2009; Lane et al., 2009). Most of the studies on 
hematological diseases refer integrins-ECM interactions as key mechanisms involved in 
tumor progression, whereas well identified genetic hits occurring on HSCs would be 
the major beginners of the oncogenic process (reviewed in Tefferi and Gilliland, 2007).  
Presently, the acceptance that the BM microenvironment is important in 
supporting leukemia stem cells survival has conducted to the rational development of 
therapies that target microenvironment molecules (reviewed in Konopleva et al., 2009;  
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Lane et al., 2009). For instance, inhibition of α4β1 integrin - FN interaction in AML 
patients increases their sensibility to chemotherapy (Matsunaga et al., 2003).  
Emerging data suggests the balance between ECM production and degradation 
(turnover) may be crucial for normal (versus malignant) organ function, while it may 
also represent a way to detect tissue damage (alterations), in particular situations. In 
BM, mononucleated cells from healthy donors continuously produce MMP-9 and 
TIMP-1 (a MMP inhibitor), whereas AML and CML blast cells additionally secrete MMP-
2, representing a potential marker for dissemination in myeloproliferative 
malignancies (Ries et al., 1999). Nevertheless, the role of the BM ECM in the 
pathophysiology of hematological disorders has remained controversial. Although 
microenvironment may not initiate clonal proliferation, it should somehow favor the 
progression of the disease. Thus, microenvironment analysis will be important to 
develop effective regimens that allow for elimination of a specific clone in human 
patients. For that reason, we will provide some examples on the role of 
microenvironment, in   particular    ECM,   in   BM malignancies.    
The MPS PMF is a remarkable model in which deregulation of the stem cell 
niche is of great importance in disease development (Lataillade et al., 2008). In a 
typical case of PMF, hematopoietic cells in BM are replaced by collagen fibrosis 
(although other ECM proteins are also increased), impairing the patient's ability to 
generate new blood cells resulting in a progressive pancytopenia (Reilly, 1997). An 
ineffective megakaryocytopoiesis leads to an excessive concentration of abnormal MKs 
which release specific growth factors (like TGF-β) essential for fibroblast activation 
and, consequently, collagens, FN and other ECM molecules production (Schmitt et al., 
2000; Kuter et al., 2007). Additionally, not only increased production of ECM occurs in 
PMF but there is also an imbalance between MMPs and TIMPs that may contribute to 
BM fibrosis (reviewed in Wang, 2005). In CML, imature CML cells have lower adhesion 
to stromal cells and FN as well as lower engraftment potential than normal HSC (Peled 
et al., 2002), a feature that may account for their exit to peripheral blood.  
In MDS, alterations in adhesive proprieties of myeloid progenitors (see above) 
are cell-autonomous and confer cell susceptibility to apoptosis (Raza et al, 1995).  
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However, changes in BM stroma, namely on ECM, have already been detected in some 
MDS patients, suggesting again a role for microenvironment in MDS progression 
(Tennant et al., 2000; Tauro et al., 2001).  Remarkably, increased cell death in MDS can 
be followed by increased proliferation, likely of selected and well adapted cell clones, 
and in this case progression to AML occurs. In normal hematopoiesis, α4β1 and α5β1 
integrin-mediated interactions between progenitor cells and FN are critical for 
progenitor cell survival. Also in AML, adhesion of blast cells to stroma via β1 
(principally α4β1) and β2 integrins, seems to inhibit apoptosis in a proportion of cases 
(Denkers et al., 1992; Liesveld et al., 1993). 
 
Angiogenesis: a link between BM microenvironment and BM diseases 
As mentioned above, BM microenvironment has a role in hematological 
disorders progression, but may also create the appropriate conditions for disease 
initiation. Of particular interest is the frequent progression from an MDS to an AML, 
during which the specific and most relevant microenvironment factors involved are 
largely still unknown. This secondary AML is usually more aggressive that de novo AML, 
being of outmost importance to uncover the mechanisms behind MDS, de novo AML 
and secondary AML. These can help in finding new therapeutic approaches 
appropriated for each type of pathology. Angiogenesis is an important event that 
mediates the progression from a chronic to a more acute and aggressive pathology, 
and its significance in hematological malignancies has just beginning to be explored 
(reviewed in Shadduck et al., 2007). Angiogenic factors may be produced by fibroblasts 
in the BM stroma and by immune cells (reviewed in Mangi and Newland, 2000), but 
their availability in BM may be regulated not only at gene expression level, but also by 
microenvironment elements. Both MDS and AML are associated with a substantial 
increase in BM vascularity as well as increased levels of various angiogenic factors, in 
cluding VEGF, basic FGFs, angiogenin, Ang-1, PDGF, HGF, epidermal growth factor 
(EGF), tumor necrosis factor-α (TNF-α), and TGF-α and TGF-β (Aguayo et al., 2000; 
Master et al., 2001; reviewed in Albitar, 2001). Malignant cell proliferation, 
angiogenesis and VEGF expression are linked in AML, as well as MMP-2 and/or MMP-9   
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expression (De Bont et al., 2001). In addition, MMPs correlate with aggressive ALL 
(Kuittinen et al., 2001). Increasing VEGF levels significantly correlate with shorter 
survival of patients with MDS and AML (Verstovsek et al., 2002). Nevertheless, higher 
levels of cellular VEGF and lower levels of its receptor KDR are seen in MDS more than 
in AML (Verstovsek et al., 2002; reviewed in Albitar, 2001). This fact is in agreement 
with a significant increase of BM microvascular density in MDS and de novo AML 
compared with healthy donors. Surprisingly, in MDS, microvascular density 
significantly decreases upon transformation to AML, which microvascular density was 
also significantly lower than in de novo AML (Keith et al., 2007).  
ECM has a key role in storing/retaining soluble factors, being proteolic enzymes 
important regulators of soluble factors bioavailability. For instance, VEGF levels 
correlate with MMP-2 and MMP-9 activity in human breast cancer (Munaut et al., 
2003). Also, in glioblastoma, HIF1α, the direct effector of hypoxia, induces the 
recruitment to tumor area of BM-derived cells that produce MMP-9, which in turn is 
essential and sufficient to initiate angiogenesis by increasing VEGF bioavailability (Du 
et al., 2008).  
It is not known if the type or amount of ECM molecules are important in this 
process, but the existence of appropriate binding sites for certain growth factor on 
ECM molecules strongly suggest these may be necessary. In this context, FN contains 
three heparin-binding and syndecan (a heparan sulfate) domains. Interestingly, the 
two longer forms of VEGF, VEGF189 and VEGF206, are not found freely in the media, 
because they are bound to the cell surface or ECM, via heparin-binding sites (Houck et 
al., 1992).  However, VEGF121 is a nonheparin-binding protein, freely diffusible (Houck 
et al., 1991). VEGF165 has intermediated proprieties, being found in a soluble form but 
also bounded to ECM. Activity of the serine protease plasmin and MMP-9 can cleave 
the bounded forms of VEGF, in a colorectal cancer cell line, releasing a soluble factor 
capable of stimulating endothelial cell growth (Houck et al., 1992; Hawinkels et al., 
2008). Also, heparin, heparan sulfate, and heparinase all induce the release of VEGF165 
and VEGFl189, in a human embryonic kidney cell line (Hawinkels et al., 2008), 
suggesting heparin-containing proteoglycans as  candidates for VEGF-binding sites. All 
 19 
 
INTRODUCTION 
these data together suggest that ECM, in particular FN, can regulate VEGF 
bioavailability in angiogenic processes. It remains to elucidate which signaling 
pathways regulate ECM and if it is an important issue in angiogenesis and tumor 
progression in hematological tumors.  
A good candidate to regulate FN in vessel formation is the Notch signaling 
pathway (Trindade et al., 2008). Notch signaling regulates the self-renewal of HSPCs 
and is also involved in various hematological malignancies (reviewed in Leong and 
Karsan, 2006), for example, acute T-lymphoblastic leukemia (Weng et al., 2004; Tohda 
et al., 2005; Lee et al., 2007) and MDS (Länger et al., 2004; Li et al., 2005; Fu et al., 
2007; Qi et al., 2008). The role of Notch signaling in oncogenesis is controversial, and 
because most cancers express more than one type of Notch ligand and/or receptor, 
the overall expression profile of these ligands/receptors may ultimately determine 
whether this pathway will be oncogenic  or  in oncosuppressive.  Also cell type and the 
presence of specific soluble factors in tumor microenvironment influence the effect of 
Notch signaling in oncogenesis (reviewed Leong and Karsan, 2006). This suggests that 
Notch signaling may be involved in regulating BM microenvironment in hematological 
diseases (possibly also through FN production or release).  HPCs isolated from MDS 
patients display a disrupted Notch signaling. Furthermore, there was a marked 
reduction in the plasticity of mesenchymal stem cells of MDS patients compared with 
those of normal BM donors, in neurogenic and adipogenic differentiation ability and 
hematopoiesis supporting capacity in vitro (Varga et al., 2007).  
As a final remark, BM microenvironment engages a complex mixture of cells, 
ECM molecules, growth factors and cytokines, which can exert reciprocal influence on 
each other’s availability. A sum of all these factors will activate (and additionally being 
activated by) specific signaling pathways that will certainly contribute to hematological 
dysfunctions. In this Thesis, we have exploited some of the interactions between ECM 
molecules and angiogenic growth factor bioavailability in the setting of hematological 
malignancies. 
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Similar to what is known for solid tumors, angiogenesis is an important event in 
hematological tumors progression. In detail, the pro-angiogenic factor VEGF is 
overexpressed in some BM diseases (like MDS and AML), being correlated with 
increased vessel density.  In solid tumors, the ECM and MMPs have been implicated in 
VEGF retention and bioavailability, thus conditioning tumor angiogenesis. Among the 
known ECM components, FN is frequently detected in solid tumors, where is known to 
regulate several cellular and structural functions. Much less is currently known 
concerning the role of ECM, MMPs and VEGF availability in hematological tumors.  
 
Based on this information, the general aim of our study was to know if the BM 
microenvironment concerning ECM components, angiogenic factors availability, etc, 
differs between MDS and AML and what role might such factor be playing in disease 
progression.  
 
To answer that, we proposed the following specific aims:  
 
 Is VEGF bound to FN or is it on its soluble form in BM from MDS or AML 
patients? 
 
 Are MMPs involved in VEGF bioavailability in BM from MDS or AML patients? 
 
 Do FN amounts vary between MDS and AML and how is its expression 
regulated in these BM? 
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Human samples 
BM biopsies from 11 MDS and 9 AML (Table S1) patients were obtained after 
informed consent, according to IPOLFG guidelines. Biopsies were made by aspiration of 
BM cells from iliac crest. 
Samples were centrifuged at 1400 rpm for 5 minutes, at room temperature (RT) 
and the supernatant was stored at -80ºC for further analysis. The pellet was 
ressuspended in 10ml of sterile phosphate buffered saline buffer (PBS)/ 
ethylenediaminetetraacetic acid (EDTA) (Table S2), added to 3ml of Lymphoprep (Axis-
Shield) and centrifuged at 1800 rpm for 20 minutes, at RT. Then, a density gradient is 
formed and the white ring that contains the BM mononucleated cells was removed 
and ressuspended in Dulbecco’s Modified Eagle Medium (DMEM), 10% fetal bovine 
serum (FBS), supplemented with glutamine, antibiotic and antimicotic (complete 
medium), and centrifuged at 1200 rpm for 5 minutes, at RT. The pellet was 
ressuspended in 1ml of DMEM 10% FBS, the cells were counted in a Neubauer 
counting chamber and used for in vitro assays or ressuspend in Trizol (Invitrogen ™) 
(1ml/ 106 cells) and stored at -80ºC for further RNA isolation.  
 
RNA isolation 
To extract RNA, BM mononucleate cells stored in Trizol were brought for 5 
minutes to RT to permit total dissociation of nucleoproteins complex. The next steps 
were performed on ice to prevent RNA degradation. Cell lysate was mixed with 
chloroform (1/5 volume of Trizol), vortexed for 15 seconds, incubated 15 minutes on 
ice and then centrifuge at 14000 rpm, 4ºC for 25 minutes. After centrifugation, three 
phases were formed, the one in the top is a colorless aqueous phase and contains 
RNA, in the middle there is an interphase with DNA and the bottom phase is red, 
containing proteins and lipids.  The supernatant (aqueous phase) was transfer to a 
fresh microtube with isopropanol (1/2 Trizol volume) and this mixture incubated 
overnight (ON) at -20ºC. Subsequently, precipitated RNA was centrifuged at 4ºC, 
14000 rpm, for 20minutes, and the supernatant discarded. The pellet was washed with 
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70% ethanol (diluted in diethyl pyrocarbonate (DEPC)-treated H2O), centrifuged at 
14000 rpm for 10 minutes at 4ºC, the supernatant discarded and the microtubes were 
left open until the remaining ethanol was completely dried. The pellet obtained was 
then solubilized in 10µl of RNA-free water (DEPC water), and quantified in a Nanodrop 
(Thermo Scientific Nanodrop 2000 Spectophetometer, program Nanodrop 
2000/2000c). For that, 1,3µl from each sample was used, as well as a blank (RNA-free 
water). 
 
cDNA synthesis 
To synthesize cDNA from RNA, 1µg of RNA was used. A mix was prepared with 
the correspondent volume of RNA for 1 µg, 1µl of random hexameric primers 
(hexadeoxyribonucleotides; Invitrogen), (provide internal site for mRNA to synthesize a 
first strand of cDNA), and water for a final volume of 15µl.  This mix was incubated in a 
Thermocycler (Biometra) 10 minutes at 70ºC, and 3 minutes at 4ºC; during this period 
11µl of enzyme mix was added and the incubation remains for 1.30 hours at 42ºC, and 
15 minutes at 75ºC. The enzyme mix contains 4µl First Strand 5x buffer (Invitrogen ™), 
4µl DNA nucleotides dNTPs (deoxyribonucleoside triphosphates; Invitrogen™) at 5nM 
each, 2µl 0,1M Dithiothreitol (DTT; Invitrogen™), 1µl ribonuclease inhibitor (RNase out; 
Invitrogen™) and 0.5µl Reverse Transcriptase Superscript III RT (Invitrogen™). The 
cDNA was then store at -20ºC.  
 
Real-time polymerase chain reaction (RT-PCR) 
To validate the presence of cDNA, 18S gene was amplified by RT-PCR, in each 
sample. 
 A mix was prepared containing, for each sample, 18,15µl H2O, 2,5µl 10x buffer 
(InvitrogenTM ), 2µl dNTPs (InvitrogenTM ), 0,75µl MgCl2 (InvitrogenTM ), 0,5µl forward 
and reverse primers for 18S gene (Sigma; Table S3), 0,1µl HotStarTaq DNA Polymerase 
(InvitrogenTM ), and 0,5µl cDNA. Next, mixes were incubated in a thermocycler (Biome- 
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tra) for 50 cycles of repeated heating and cooling of the reaction, for melting and 
enzymatic replication of the DNA. 
 Three µl of loading buffer (Table S4) were added to 10µl of each PCR product, 
the mix was loaded in a 2% agarose gel (Table S5) and run in an electrophoresis 
apparatus with 0,5x Tris/Borate/EDTA (TBE- Table S6) at 145V, for 30min. DNA bands 
were visualized in an imaging system under ultraviolet light (BioDocAnalyze digital, 
Biometra). 
 
Quantitative real time polymerase chain reaction (RQ-PCR) 
The relative expression of Notch1, Jagged1, Dll4, Hey1, Hey2 and FN was 
determined by RQ-PCR.  
 First, 10µl SYBR Green PCR Master Mix kit (contains SYBR Green I dye, ROX 
passive reference dye, HotStarTaq DNA Polymerase, and a dNTP mix in an optimized 
buffer; Applied Biosystems), 0,4µl forward primer (Sigma; Table S3), 0,4µl of reverse 
primer (Sigma; Table S3), 7µl of H2O, and 0,2µl bovine serum albumin (BSA) 2% were 
added to each 0,2µl of cDNA sample, in a Micro-Amp optical 96-well plate. The plate 
was then centrifuge at 1460rpm for 2 minutes and analyzed in ABI PRISM 7900HT 
Sequence Detection System (Applied Biosystems), using the SDS2.3 software. The 
relative expression of each gene was calculated with RQ Manager 1.2 software, using 
the comparative method 2-ΔCt. 
 
Protein quantification  
  The protein content from BM supernatants was quantified with the Dye 
Reagent Concentrate Protein Assay (Bio-Rad). First, several dilutions of BSA were 
prepared in order to obtain a standard curve: 1mg/ml, 1,5mg/ml, 2,5mg/ml 5 mg/ml 
10mg/ml.  One µl of each BSA standard solution or 1µl of BM supernatant were diluted 
in 500µl of dye reagent, previously diluted 1:5 in water, vortexed, incubated 5 minutes,  
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at RT and their absorbance measured at 595nm (Gene Quant pro, RNA/DNA 
Calculator). 
 
Enzyme Linked Immunosorbent Assay (ELISA) 
  To quantify VEGF protein in supernatants of BM biopsies or from BM cell 
cultures, an ELISA for human VEGF (Calbiochem) was used; all the solutions and 
protocol where provided by the manufacturer. 
Initially, known concentrations of VEGF were prepared (1000, 250, 62,5, and 
31,5 pg/ml), in order to construct a standard curve. Then, 100µl of Assay Diluent RD1W 
and 100µl of each sample (diluted 1:2 in Assay Diluent) or VEGF standards were mixed 
in each well of a 96-well plate coated with anti-human VEGF antibody, and incubated 
for 2 hours at RT with gently mixing and covered with an adhesive strip; this assay was 
made in duplicate. After this, wells were washed with 1x Wash Buffer, three times, and 
then 200µl of anti-VEGF antibody HRP-conjugated were added and incubated for 2 
hours at RT, with gently mixing. Next, 200µl of Substrate Solution were added to each 
well and incubated for 25 minutes at RT. Finally, 50µl of Stop Solution were added to 
each well to stop the enzymatic reaction. The intensity of the yellow solution obtained 
is proportional to the amount of VEGF protein in the sample, and their respective 
absorbance were determined at 450nm in a Bio-Rad iMark microplate reader, program 
MPM6. 
 
Western-Blotting 
Analysis of protein content in BM supernatants was performed by western-
blotting.  First, proteins were separated by sodium dodecyl sulfate -polyacrylamide gel 
electrophoresis (SDS-PAGE) that allows the sorting of proteins by their molecular 
weight and charge. SDS-PAGE gel composition and porosity is chosen based on the 
specific weight and composition of the target proteins to be analyzed. Here, an 8%  gel  
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was used since we wanted to separate proteins of 25-200KDa size. This gel is 
composed of two acrylamide mixes: the resolving or separating gel (Table S7), and, on 
top, a stacking gel (Table S8) with large pores that compresses proteins in a thin 
starting zone.  
As proteins have varying charges and complex shapes, they are usually 
denatured in the presence of a detergent (in this case SDS) that coats them with a 
negative charge and, therefore, they will run to the positive pole when electric current 
is applied to the gel.  
In the next step, proteins were denatured adding Laemmli buffer (10% β-2-
mercaptoethanol in loading buffer - Table S9) to equal volume of protein (equivalent 
to 50µg), and heating at 100ºC for 5 minutes. β-2-mercaptoethanol denatures proteins 
via its ability to cleave disulfide bonds, disrupting both the tertiary and the quaternary 
structure of the proteins. For positive control of FN staining, 2µl of 0,1% FN from 
bovine plasma (Sigma) was also denatured like samples. Then, samples, positive 
control and 5µl of protein ladder (Benchmark Pre-stained protein ladder) with 
molecular weights standard, were loaded in the gel, and run at 120V for 1.30 hours in 
an electrophoresis apparatus filled with running buffer containing 25 mM Tris, 192 mM 
glycine and 0.1% SDS (TGS, Bio-Rad).  
The following step is the transfer of the proteins from the gel to a nitrocellulose 
membrane, by electric current, and the exposition of proteins on thin surface of the 
membrane for detection. This transfer is performed in a Criterion Blotter ™ (Biorad) 
filled with transfer buffer (table S10), ON, 4ºC, at 105V. To prevent the non-specific 
interaction of the antibody, a blocking step was performed incubating the membrane 
with 5% milk in TBS, Tween 0,1% (Table S11), for 1 hour, at RT, with agitation (Movil-
rod, P Selecta).  
Then, the membrane was incubated with primary antibody anti-FN (1:1000; 
F3648, Sigma) diluted in 5% milk TBS, Tween 0,1% (Table S11), at 37ºC for 2 hours, 
with agitation. After washing with three timers with TBS, Tween 0,1%, the membrane 
was  incubated for 1 hour with an anti-rabbit  secondary antibody conjugated with hor- 
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seradish peroxidase (HRP) enzyme (1:5000; 31460 Thermo Scientific), at RT, and finally 
wash three times with TBS, Tween 0,1%. At the end, the bands corresponded to the 
specific protein (FN or VEGF) were detected by incubating the membrane with the 
substrate for HRP enzyme (Pierce ECL - super sinal west pico chemiluminescent 
substrate; Thermo Scientific), and observed in a Bio-Rad molecular image system, 
Chemidoc XRS+, with Image Lab software. The bands obtained were quantified with 
ImageJ software (densitometric analysis). 
 
Co-immunoprecipitation  
Co-immunoprecipitation permits detect the presence of protein complexes, in 
this case, VEGF bounded to FN, in a given sample. This technique starts with the 
purification of FN, diluting 50µg of total protein with 500µl of PBS, BSA 0,5% and 
incubating it with the primary antibody, anti-FN (F3648, Sigma), ON, at 4ºC.  
In the next day, protein G sepharose beads were washed with ethanol, diluted 
1:1 in PBS 1x (Table S12), and centrifuged at 3000rpm, 4ºC for 2minutes. Then, 
supernatant was discarded; this procedure was repeated three times. At the end, the 
pellet (with was ressuspended in 1ml of PBS 1x. Then, 50µl of these beads were diluted 
with the FN-anti-FN antibody complex and incubated for 3 hours, at 4ºC, with gently 
mixing. Next, this mix was centrifuged at 2500rpm for 10 minutes, at 4ºC, supernatant 
was discarded and washed three times in PBS 1x. The pellet obtained was diluted in 
20µl of Laemmli buffer (10% β 2-mercaptoethanol in loading buffer; Table S9), and 
heated at 95ºC for 2 minutes, to denature proteins and separate the proteins from 
beads. After this procedure, 50g of purified FN from BM samples were loaded in a 
SDS-PAGE gel, following the Western-blotting protocol. In this case, nitrocellulose 
membrane was incubated with an antibody anti-VEGF (1:500; SC7269, Santa Cruz), 
followed by anti-mouse (1:5000; 31430 Thermo Scientific), in order to detect FN-VEGF 
complexes present in BM samples. 
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Gelatin Zymography 
  Gelatin zymography was performed on supernatants of BM biopsies to detect 
MMPs. For this technique, a 10% polyacrylamide gel with gelatin (Table S13) was used 
due to MMPs proteolitic activity on gelatin. A stacking gel for concentrating protein 
was also used as for Western-blotting. 
A supernatant volume equivalent to 50 g of total protein was diluted in equal 
volume of loading buffer, and run in an electrophoresis apparatus, in TGS 1x, at 140 V 
for 2 hours. Then, the gel was rinsed in 2.5% Triton X-100 (Table S14) and incubated in 
the same solution for 1 hour, at RT, with gently mix, in order to remove SDS. The gel 
was rinsed two times in 1x low salt collagenase buffer (Table S15) and incubated in this 
solution, ON at 37ºC, to optimize gelatin digestion by MMPs. At the end, the gel was 
washed with water and stained with Comassie brilliant blue (Sigma) working solution 
(a dye to stain proteins, Tables S16, S17 and S18) for 1 hour.  
 
Imunohistochemistry 
BM biopsies were included in paraffin wax, 3m sections were obtained, 
rehydrated and went through a heated-induced antigen retrieval protocol (high 
temperature, Pt module). All these steps were performed in Anatomical Pathology 
Department at IPO, following their own protocols. 
Sections were blocked for endogenous peroxidases with 10% H2O2 in methanol, 
for 20 minutes.  Next, to reduce unspecific antibody staining, sections were incubated 
in PBS 0,5%, BSA 1%, FBS 2%, for 1 hour, RT Then, they were washed in water and PBS 
1x and incubated ON, at 4ºC with the primary antibody, Factor VIII (1:30; Dako M0616, 
clone F8/86), diluted in PBS 0,5%, BSA 1%; this antibody is specific for blood vessels 
and MKs. After a three times wash with PBS 1x, 5 minutes, sections were incubated 
with the secondary antibody anti-mouse conjugated with peroxidase (DAKO), for 30 
minutes, at RT and washed three times in PBS 1x. At the end, sections were incubated 
(at maximum, for 10 minutes) with 3,3' - diaminobenzidine (DAB), an organic substrate 
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for hydrogen peroxidases, which became dark brown after being oxidized. After 
washing in water, sections were stained for nucleus with haematoxilin for 40 seconds, 
and washed in tap water. At the end, section were dehydrated in 50, 70, 90, and 100% 
ethanol,  for 1 minute each,  1 minute in xilol and the slides mounted with Entellan 
(Merck). 
Vessel density was obtained counting the number of vessel stained with Factor 
VIII antibody in five different fields in each section (40x objective). 
 
Immunofluorescence 
  Paraffin section were treated as for immunohistochemistry (see above) until 
the blocking step with PBS 0.5%, BSA 1%, FBS 2%, for 1 hour, at RT.  After this, sections 
were incubated with primary antibody, anti-FN (1:100, F3648, Sigma) and anti-VEGF 
(1:500; SC7269, Santa Cruz), ON, at 4ºC. In the next day, they were washed three times 
with PBS 1x, 5 minutes, and incubated one hour with the appropriated secondary 
antibody, Alexa fluor 488 goat anti-rabbit  (A-11008, Molecular Probes),  or  Alexa fluor 
594 goat anti-mouse (A-11005, Molecular Probes).  Finally, sections were washed in 
PBS 1x and slides mounted with Vectashield with DAPI (nuclear staining - Vector, H-
1200) and examined under a fluorescent microscope (20x objective).  
 
In vitro assays 
 About 2x104 mononucleated cells obtained from MDS and AML BM biopsies 
were seeded per well of a cell culture plate with 24 wells, previously coated with 0,1% 
FN or without coating, in DMEM 10% FBS medium. Cells grow under controlled 
conditions, at 37ºC, 5% CO2. In some cases, cells grow for 3-4 weeks, and a culture of 
adherent cells (stromal cells) was obtained; in other situation, cells were maintained in 
culture for shorter periods and, in this case, BM cells from several lineages were 
present. 
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Inhibition of MMPs 
Cells grow on FN for two days and then the medium was changed to DMEM 1% 
FBS (to avoid the effects of a higher percentage of FBS). In some wells, 2,5mM EDTA, a 
zinc-chelanting agent, was added in order to inhibit MMPs. In the next day, the 
medium was removed and stored at -80ºC until used in gelatin zymography or in ELISA 
assay for VEGF quantification. 
Inhibition of Notch pathway 
Notch pathway was inhibited in BM stromal cells with DAPT (Sigma), a -
secretase that cleaves cell membrane proteins, including Notch receptor.  One day 
before the assay, medium was changed to DMEM 1% FBS and in some wells were 
added 10µM N-[N-(3,5-difluorophenacetyl)-L-alanyl]-(S)-phenylglycine t-butyl ester 
(DAPT) or 1µl of dimethyl sulfoxide (DMSO), in duplicated. DMSO is used as a control, 
since DAPT is dissolved in this organic solution. The cells were exposed to this compost 
by 16 hours. Next, medium was removed and stored at -80ºC, cells were isolated with 
trypsin (Gibco) and stored in Trizol at -80ºC for RQ-PCR. 
 
Statistic analysis  
  Statistic analysis was performed with GraphPad Prism v.5.0 software, using 
unpaired t and correlation test (both with a confidence interval of 95%). 
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VEGF is bound to FN in MDS and AML BM patient samples 
ECM can function as a reservoir of soluble factors, regulating their availability in 
several biological events. As a first approach to study its importance in the BM 
microenvironment, we wanted to know if in BM malignancies VEGF, a major 
angiogenic factor, was bound to FN. Co-immunoprecipitation is a technique that allows 
the detection of protein complexes, so we used that to evaluate the association 
between FN and VEGF in BM MDS and AML patient samples. The antibody used to 
detect VEGF is specific for VEGF189, VEGF165 and VEGF121 isoforms, being VEGF189 and 
VEGF165 able to bind ECM molecules (insoluble forms).  
In fig. 1A, the bands obtained represent VEGF protein that was attached to FN 
in several samples of BM from MDS and AML patients. After densitometric analysis of 
these bands, a quantification of VEGF-FN complexes was achieved (fig. 1B). 
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Figure 1. BM from AML patients have more VEGF bound to FN than MDS patients BM. (A) Co-
immunoprecipitation of VEGF with FN obtained from AML and MDS patient samples.  A band 
corresponding to VEGF165 dimer can be seen at approximately 36kDa. (B) Optical density of 
scanned western-blots from the same samples. p=0,0117 
 
These results show that VEGF can be bound to FN in BM, and that this 
association was higher in AML patients than in MDS patients.  
 
MMPs are important for the release of VEGF bound to FN 
MMPs are zinc-dependent endopeptidases that degrade the ECM, which can 
lead to the release of soluble factors bound to ECM. To investigate if MMPs are 
important for the release of VEGF bound to FN in hematological patients BM samples, 
we performed an in vitro assay with cells isolated from BM biopsies. These cells grew 
in the presence or absence of EDTA (chelates ions including zinc, and therefore blocks 
MMP activity) and after three days in culture, the medium was analyzed in terms of 
MMPs activity and VEGF concentration, by gelatin zymography and ELISA assay, 
respectively. 
By zymography we detected the inhibition of MMP-9 activity in the presence of 
EDTA, in both diseases, more evident for AML patients. These results also show a 
higher concentration of MMP-9 in  the medium from AML cell cultures than  from MDS  
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cells (Fig. 2A), which was confirmed after quantification of the bands by densitometric 
analysis (Fig. 2B). 
 
 
 
Figure 2. MMPs are inhibited by EDTA, especially in AML patient cell cultures. (A) Zymograms 
showing MMP-9 and MMP-2 activity in the absence (-) or presence (+) of 2,5mM EDTA in cell 
culture medium from AML and MDS patients. (B) Optical density for (B.1) MMP-9 and (B.2) 
MMP-2 bands shown in the zymogram.    
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The analysis by ELISA of VEGF levels in the medium from these cultures (fig. 3) 
shows that in AML patients a considerable decrease of soluble VEGF occurs when 
MMP activity is inhibited. The soluble VEGF in MDS cell cultures was measured, but 
could not be detected in these samples.  
 
Figure 3. Levels of soluble VEGF decrease in cell culture medium from AML cells in the 
presence of MMPs inhibitor. VEGF was measured by ELISA assay in cell culture medium from 
AML patients in the absence (-) or presence (+) of EDTA.  p=0,058  
 
These results demonstrated the importance of MMPs activity in the release of 
VEGF produced by BM cells, and that they are active in MDS and AML BM.  
 
Soluble VEGF is more abundant in MDS patients BM samples 
Given that higher amounts of VEGF bound to FN were detected in AML cells, 
comparing with MDS cells, we wonder if there is also a difference in its soluble form in 
BM supernatants from both groups of patients. For that, soluble VEGF was measured 
by ELISA assay. After quantification by spectrophotometry, it is evident that MDS BM 
supernatants have more soluble VEGF than AML supernatants and that this difference 
has statistical significance (fig. 4). 
 
 
 54 
 
RESULTS 
 
 
Figure 4. Soluble VEGF levels in BM supernatants are higher in MDS patients than in AML 
patient samples. Levels of VEGF proteins were quantified by ELISA assay, in supernatants from 
BM biopsies from MDS and AML BM biopsies. p= 0,0388 
 
MMP-9 and MMP-2 are more concentrated in BM biopsies from MDS patients 
 Since we had observed that MMPs were important for the release of VEGF from 
BM cells in vitro, we investigated the levels of MMP-9 and MMP-2 activity in BM 
supernatants from AML and MDS patients.   
MMPs activity from supernatants obtained from BM biopsies were measured 
by zymography, as above. MMP-9 and MMP-2 activity was detected in the majority of 
patients with both diseases (Fig. 5A). 
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Figure 5. The amounts of MMP-9 and MMP-2 are increased in MDS patients.  (A) Zymogram 
showing the presence of bands corresponded to MMP-9 and MMP-2 in MDS and AML BM 
supernatants. (B) Optical density for (B.1) MMP-9 and (B.2) MMP-2 bands shown in the 
zymogram. B.1) p=0,1312;  B.2) p=0,4073 
 
Densitometric analysis of MMP-9 and MMP2 bands obtained by zymography 
show a trend for an increase (not statistically significant) in the amounts of both types 
of MMPs in supernatants from MDS patients, comparing with AML patients (Fig. 5B) 
samples. This analysis also shows that MMP-9 is more concentrated in all BM patient 
samples than MMP2.  
These results demonstrate that BM cells from MDS patients produce more 
MMPs than AML BM, which can be important for the release of soluble VEGF from BM. 
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MMP-9 levels are correlated with soluble VEGF in BM from MDS patients 
 A correlation test (with a confidence interval of 95%) for MMP-9 and soluble 
VEGF measured above demonstrated a positive relation (r) between these two factors 
in BM from MDS patients.  This means that when the levels of MMP-9 increases in BM, 
soluble VEGF also increases in these patients (Fig. 6).  
 
Figure 6. A positive correlation is seen between MMP-9 and soluble VEGF levels in BM 
supernatants from MDS patient samples.  This graph was obtained by linear regression of 
results obtained by zymography (densitometric analysis of MMP-9 bands) and by ELISA 
(concentration of VEGF). p=0,0201, r=0,5114 
 
Although done on a limited number of patient samples, together these results 
suggest that the higher amounts of soluble VEGF in MDS BM patients may be due to its 
proteolytic release from FN present in BM and that elevated concentration of MMPs 
contributes to such phenomena. Conversely, in AML BM, VEGF is detected mainly 
bound to FN, possible due to a lower concentration of MMPs produced by the BM of 
these patients. 
 
MDS patients have more FN in BM than AML patients 
 Next, we determined by Western-blotting if the amount of FN differed between 
MDS and AML patient samples (Fig. 7).  
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Figure 7. FN is more abundant in MDS BM samples. (A) Western-blotting for FN detection. (B) 
Optical density for the bands corresponded to FN monomer (220kDa) and (C) 
immunofluorescence staining for FN  (green) in BM sections (scale bar=50µm). (B) p=0,0411 
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FN was present in all BM samples, but MDS patient samples have more FN 
protein in their BM than AML patients. This difference has statistical significance.  
BM from MDS patients exhibit a more angiogenic phenotype than from AML  
patients 
 It has already been shown that both MDS and AML BM have increased vessel 
density and increased VEGF levels compared to normal BM, which is illustrative of the 
highly angiogenic and thus, aggressive phenotype of these diseases. By 
immunofluorescence, we saw that MDS patients BM sections have, in general, more 
VEGF in the cytoplasm of BM cells (Fig. 8). 
 
  
Figure 8. MDS BM have more FN and cytoplasmic VEGF than AML BM. FN (green) and VEGF 
(red) were detected by immunofluorescence in BM sections from MDS and AML patients (scale 
bar=50µm). 
 
 Although we detected more soluble VEGF in MDS BM and more VEGF bounded 
to FN in AML BM, the protocol used for immunofluorescence (with organic solvents) 
should caused the lost of soluble VEGF.  These results suggest that MDS BM have more 
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VEGF than AML, regardless of its localization within BM. 
 Next we stained (fig. 9A) and counted (fig. 9B) BM blood vessels in BM sections 
from MDS and AML patients with an antibody against Factor VIII; this antibody also 
stains MKs.   
 
 
 
Figure 9. MDS patient samples have more BM vessels than AML patients.  (A) 
Immunohistochemistry in BM from MDS and AML patients showing stained blood vessels 
(arrows) and MKs (arrowheads) (scale bar=50µm). (B) The quantification of these vessels was 
performed counting five fields with a 40x magnification lens in each BM section. p=0,0369.  
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With these results we concluded that MDS patients present more BM vessels 
and that this angiogenic phenotype is associated with less VEGF bound to FN and 
consequently to more soluble VEGF present in the BM microenvironment.  
 
Notch pathway is activated in both MDS and AML patient BM samples 
Next, to exploit in more detail possible molecular mechanisms involved in the 
distinct angiogenesis profile and potential by MDS and AML patient BM samples, we 
investigated the involvement of the Notch pathway.   
Notch pathway is altered in several hematological diseases. The Notch family 
comprises cell membrane receptors (NOTCH1, 2, 3 and 4), which are activated by 
Delta-like (1, 3, or 4) or Jagged (1 and 2) ligands. The primary targets genes of Notch-
intracellular domain are HES and HEY (1 and 2) family, which act as transcription 
factors and which expression is the best indicator of the activation of this pathway. 
We investigated the activation of Notch pathway in patients BM samples by 
RQ-PCR, detecting the expression of the following genes: HEY1, HEY2, JAG1, NOTCH1 
and DLL4 (Fig.10). In addition, we analyzed the expression of FN in the same cells to 
see if there is any relation between this signaling pathway and FN expression (Fig. 11).  
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Figure 10. Members of the Notch pathway and downstream target genes show similar 
expression in MDS and AML patient BM samples. RQ-PCR in BM cells from MDS and AML 
patients for the expression of (A) HEY1 and (B) HEY2 transcriptors factors, (C) NOTCH receptor, 
and (D) JAG1 and (E) DLL4 ligands. Results are represented as mean of Δct and have no 
statistical significance. A) p=0,678; B) p=0,8573; C) p=0,1061; D) p=0,9934; E) p=0,5537 
 
 
Figure 11. The expression of FN in BM cells from AML patients is higher than in MDS cells. 
RQ-PCR for FN expression in BM cells from AML and MDS patients. Results are represented as 
mean of Δct and the differences between the samples have no statistical significance. 
p=0,1975 
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Notch pathway activity correlates with FN expression in AML patient BM samples 
After the analysis of the expression from several molecules of Notch pathway 
and FN in BM cells, we tested the correlation between the expression of these 
molecules, using a correlation test, with a confidence interval of 95%. The correlation 
coefficient (r) can be positive or negative and this shows if the expression of FN and of 
a given member of the Notch pathway are directly or inversely proportional, 
respectively (table 1). The significant correlations are represented in fig. 12 and 13. 
 
Table 1. Correlation test. (A1, B1) indicate p value and (A2, B2) indicate correlation coefficient 
for gene expression in (A) MDS and (B) AML BM.  
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In table 1 we can observe that the correlation between the expression of FN 
and HEY1, HEY2, NOTCH, and Dll4 is positive and has statistical significance for AML 
patients (table 1B, fig. 13). However, in BM cells from MDS patients the expression of 
FN only correlates with HEY2 expression (table 1A, fig. 12).  
 
 
Figure 12. The expression of FN and HEY2 is positively correlated in MDS patients. 
Correlation curve for FN and HEY1 expression in BM from MDS patients. p=0,0560, r=0,7546 
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Figure 13. The expression of FN and elements of the Notch pathway are positively correlated 
in AML patients. Correlation curves for FN and (A)HEY1, (B)HEY2, (C) Dll4  and (D) NOTCH1 
expression in BM from AML patients. A) p<0,0001, r=0,9994; B) p=0,0011, r=0,9816; C) 
p=0,0001, r=0,9961; D) p=0,0248, r=0,8539 
 
These results show that in AML, when the Notch pathway is activated, there is 
an increase in FN expression in BM, for all patients. However, in MDS the correlation is 
only between FN and HEY2 expression.   
 
Activation of NOTCH pathway increases FN expression in AML patient BM samples   
To confirm the involvement of Notch pathway in FN regulation, we performed 
an in vitro assay where Notch was inhibited. To do that, we used cultures of stromal 
cells derived from BM biopsies of MDS and AML patients, growing in the presence or 
absence of DAPT for 16 hours. DAPT is a -secreatase that cleaves cell membrane 
proteins, including Notch. DMSO was used as a control. Then, we removed cells and 
analyzed the expression of HEY1 and FN by RQ-PCR (fig. 14).    
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Figure 15.  In MDS stromal cells the inactivation of Notch pathway does not affect FN 
expression , but does so in stromal cells from AML patients. RQ-PCR for (A, C) HEY1 and (B, D) 
FN expression 16 hours after the addition of DMEM 1% FBS (c), DMSO and DAPT inhibitor to  
BM stromal cells from (A, B) MDS and (C, D) AML patients. A) p=0,0225, B) p= 0,7852 C) p= 
0,0036, D) p=0,0471 
These results show that DAPT was able to inhibit Notch signaling, since HEY1 
expression decreases in this condition. Nevertheless, this inhibition does not affect 
expression of FN in stroma cells from MDS patients. On the other hand, in stroma from 
AML patients, the inhibition of Notch signaling significantly decreases FN expression in 
relation to the control. This in vitro assay is in agreement with the positive correlation 
found between the expression of FN and Notch pathway molecules. All together, these 
results suggest that in BM from MDS patients the expression of FN may be controlled 
by a signaling pathway other than the Notch, which seems to be a good candidate for 
FN regulation in AML BM.  
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The propose of this study was to address if BM microenvironment differs 
between MDS and AML, and what role might such factor be playing in disease 
progression. 
Angiogenesis is an important event that mediates the progression from a 
chronic to a more acute and aggressive pathology, and its significance in hematological 
malignancies has just beginning to be explored (reviewed in Shadduck et al., 2007). 
Both MDS and AML are associated with a substantial increase in BM vascularity as well 
as with increased levels of various angiogenic factors including VEGF, basic FGF, 
angiogenin, angiopoietin-1, PDGF, HGF, EGF, TNF-α, and TGF-α and TGF-β (Aguayo et 
al., 2000; Master et al., 2001). The formation of new blood vessels and their 
permeability is primarily regulated by VEGF (Connolly et al., 1989; Ferrara and Henzel, 
1989). Three isoforms of VEGF-A, VEGF165, VEGF189 and VEGF206 can be found bounded 
to the cell surface or ECM, via heparin-binding sites (Houck et al., 1992), whereas 
VEGF121 is a nonheparin-binding protein, freely diffusible. 
First, by immunoprecipitation, we detected more VEGF bounded to FN in AML 
than in MDS BM. Both in MDS and AML samples, VEGF was detected as a band of 
36KDa that may correspond to the VEGF165 isoform, which can be found bounded to 
cell surfaces or to ECM, but also as a soluble form. Nevertheless, using this technique, 
only the insoluble form could be detected in the BM samples. On the other hand, by 
ELISA, we detected a significant increase of soluble VEGF in BM from MDS samples, 
comparing with AML, which strongly suggest that VEGF bioavailability in these diseases 
may be controlled by its level of association with FN.  
In hematological tumors, MMPs expression has been shown to be upregulated 
in some leukemia, lymphomas and multiple myeloma (Barillé et al., 1997; Kossakowska 
et al., 1999; Kuittinen et al., 2001; 2003; Pennanen et al., 2008). Also in a colorectal 
cancer cell line, the activity of serine protease plasmin and MMP-9 can cleave the 
bounded forms of VEGF, stimulating endothelial cell growth (Houck et al., 1992; 
Hawinkels et al., 2008). We explore if levels of MMP-9 and MMP-2 in BM was different 
between MDS and AML patients and if these enzymes change the amounts of soluble 
VEGF. After inhibiting MMPs with EDTA in BM cultures, we show a decrease in VEGF le- 
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vels in cell cultures medium, especially for AML. In MDS cultures, MMPs were almost 
absent (even without EDTA) which was not expected because we see more quantities 
of MMPs in BM of MDS than in AML in vivo. Since these in vitro experiments were 
effectuated three days after the beginning of cell culture, we suggest the cells present 
in MDS cultures were not the ones (or at least not present in sufficient amounts) 
responsible for major MMPs production in vivo. In fact, when we grow stromal cells 
from MDS and AML BM for one month, significant increased MMPs activity was 
detected in supernatants from MDS patients (data not shown). Three days culture of 
MDS BM cells have a heterogeneous cellular composition, whereas AML cultures are 
composed essentially by AML blasts, which secrete MMP-2 and MMP-9 two hours 
after culture (Matsuzaki and Janowska-Wieczorek, 1997; Ries et al., 1999).  
This in vitro approach showed that MMPs activity regulates soluble VEGF 
amounts in BM. Altogether, these results demonstrated that in MDS BM, VEGF is 
mostly present in a soluble isoform and its availability is determined by an increase in 
MMPs activity in vivo. In AML BM, VEGF is generally bounded to FN, possibly due to a 
reduced presence of MMPs. In accordance with this, the correlation analysis shows 
that increased levels of MMP-9 in BM from MDS patients correlate with increased 
amounts of soluble VEGF in the same samples. 
Immunoflourescence staining of BM and Western-blotting analysis showed that 
MDS have more FN than AML. It is known that several cases of MDS have BM fibrosis 
(i.e. increased ECM molecules) and these can have a negative impact on patient 
survival (Lambertenghi-Deliliers et al., 1993). Perhaps, an extensive web of FN 
constitutes a good reservoir for VEGF at the beginning of MDS, in a phase that do not 
correspond to the samples we have obtained from these patients, maybe due to 
absence of symptoms. At a certain point, an increase in MMPs activity releases VEGF 
and is this soluble form that contributes to the angiogenic switch and disease 
progression. In AML, blasts occupy BM in a big extent and should not be important 
producers of FN. In addition, our group unpublished results indicate that MKs are main 
producers of ECM molecules (in particular FN) and this fact may account for fibrosis 
associated to several hematological diseases. Interestingly, we detected a trend for in- 
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creased MK numbers in BM from MDS patients, comparing with AML BM (data not 
shown).  
We also determined vessel density in our patient BM samples and confirmed a 
significant increased angiogenesis in MDS BM, which is in line with previous works and 
suggests that the different microenvironment we found in MDS BM, i.e. increased 
soluble VEGF and MMPs activity may be a major mechanism for angiogenesis in this 
disease. AML patients are also know to have an angiogenic phenotype, comparing with 
normal donors (reviewed in Albitar, 2001), but here this event may be controlled by 
other mechanism, since VEGF is mostly found bounded to FN. Alternatively, the lower 
amounts of soluble VEGF found in AML BM are still responsible for angiogenesis 
induction, but in a lesser extent, in agreement with lower vessel counts. The 
association of VEGF with ECM should inhibit VEGF ligation with its receptor in 
endothelial cells, thus, restraining angiogenesis. However, it has also been described 
that VEGF bounded to FN can enhance endothelial cell proliferation and migration in 
vitro, by direct association of this complex with the VEGF receptor flk-1 (VEGFR-1) and 
the integrin receptor α5β1, mediated by the FN heparin-II domain  (Wijelath et al., 
2002). Nevertheless, this possible crosstalk between VEGF signaling and integrin 
pathway must be fewer effective in inducing angiogenesis than the pathway activated 
by soluble VEGF, since we (and others) show that MDS BM are more angiogenic than 
AML BM.  In accordance to this, VEGF-KDR (VEGR-2) signaling has been demonstrated 
to have major impact in AML angiogenesis, in contrast with VEGF-VEGFR1 (Padró et al., 
2002).  
Notch signaling regulates the self-renewal of HSPCs, being involved in various 
hematological malignancies (reviewed in Leong and Karsan, 2006). This signaling 
pathway is also important in tumor angiogenesis. Several studies have documented 
the expression of Notch components in tumor vessels, most remarkably Dll4 (Mailhos 
et al., 2001; Patel et al., 2005). The overall effect is general and involves establishment 
and maintenance of a stabilized endothelial cell network by inhibiting the formation of 
new endothelial sprouts, attenuating endothelial cell proliferation or apoptosis, or 
decreasing VEGFR expression (reviewed in Leong and Karsan, 2006). To our knowledge,  
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nothing has been described about the effect of Notch signaling in angiogenesis of 
hematological diseases. 
In the context of our study, we analyze if Notch pathway in MDS or AML alter 
the production of FN, influencing, in turn, VEGF availability. To do these, we examine 
the Notch pathway in patient BM by RQ-PCR, and show that the analyzed elements of 
this pathway have identical expression in cells obtained from MDS and AML BM. In 
addition, FN expression in both diseases did not exhibit statistical significant 
differences. After that, we determined correlation between FN and Dll4, Notch, HEY1 
or HEY2 expression. We demonstrate that FN expression varies proportionally with 
Notch pathway molecules, but only in AML BM. In MDS cells, FN expression correlation 
is only with HEY2 transcription factor. These results suggest that Notch pathway is not 
coordinated with FN expression in MDS BM, but may be somehow associated with FN 
in AML BM. In a functional assay using stromal cells from both groups of patients, we 
inhibited the Notch pathway and analyzed FN expression. The results obtain were in 
accordance with our in vivo analyses, since the blockage of Notch pathway 
corresponded to a decrease in FN expression, but again only in AML cultures.  It seems 
that Notch pathway, which is known to be important in embryonic and adult 
angiogenesis is activated in both diseases, but only in AML BM it regulates, directly or 
not, FN expression. During mouse embryonic angiogenesis, overexpression of the 
Notch ligand Dll4 increases the deposition of FN around the vessels (Trindade et al., 
2008), but no functional importance was given to this phenotype. In addition, 
activated Notch signaling can improve endothelial cell adhesion to the ECM due to an 
enhanced affinity state of β1 integrin receptors (Leong et al., 2002). Based on our 
functional studies with stromal cultures (which enclose, among others, endothelial 
cells), we suggest that also in angiogenesis of hematological tumors, the Notch 
signaling may be involved, maybe inducing the deposition of FN around new forming 
vessel and, by this way, stabilize the vasculature. This would happen in AML, creating 
stable and functional vessels that contribute to tumor progression. In MDS, this 
pathway does not appear to regulate FN expression and this may compromise new 
vessels stability, allowing a more uncontrolled growth of the vasculature. This is agree- 
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ment with increased angiogenesis observed in our MDS samples, but also with 
observations made by members of our group that these vessels are unstable. On the 
other hand, the increased amounts of FN we observed in MDS BM should be regulated 
by other mechanisms (e.g. involving MKs), and by this way does not seem to be 
deposited around vessels. Rather, this web of FN all over BM must accumulate VEGF at 
the beginning of the disease, which will be released by MMPs and contribute to MDS 
angiogenesis. 
As a general conclusion, we suggest that the differences found between MDS 
and AML BM microenvironment lead to different angiogenic phenotypes: in MDS, 
increased soluble VEGF (in association with high MMPs activity) activates uncontrolled 
endothelial proliferation, whereas the absence of Notch signaling regulating FN 
production/accumulation around new vessels contribute to dysfunctional vessels 
formed; in AML, VEGF is kept majorly bounded to FN, so its availability must be more 
regulated and the vessels formed are more functional due to FN stabilization. At the 
end, the different vascular niches created within BM may contribute to the dissimilar 
characteristics of each disease, for example, increased apoptosis of hematopoietic cells 
in MDS and blast survival in AML (Fig. 1).  
Thus, our results have revealed to be important to better understand MDS and 
AML phenotypes and, hopefully, in the future, to design more accurate therapeutic 
strategies for these diseases.  
As future work, we would like to better study the precise distribution of VEGF 
(soluble and insoluble forms) in relation to FN localization in MDS and AML. For that, 
we could performed confocal microscopy in BM sections after immunostainning and 
obtain three-dimensional and accurate images of BM that would allow us to better 
visualize VEGF-FN association in vivo and search for differences between MDS and 
AML. It would also important to know how the ligation between VEGF and FN is 
established, i.e., which binding domain of each molecule is involved and if other 
molecules are implicated. This could be achieved using inhibitory antibodies against 
particular binding domains in in vitro assays with BM isolated cells. 
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Figure 1. Schematic representation of MDS and AML BM microenvironment.  The MDS BM 
has more soluble VEGF and higher MMPs activity, which may be responsible for increased 
angiogenesis occurring in this disease. Notch pathway does not regulate FN expression, which 
leads to new formed vessels instability. In AML, VEGF is kept majorly bounded to FN, and 
MMPs activity is lower than in MDS BM. In such conditions, VEGF bioavailability is more 
regulated, being angiogenesis less exuberant. In addition to this, Notch pathway regulates FN 
deposition around new vessels, contributing to the formation of a more functional and stable 
vasculature.  
   
Our results concerning the Notch signaling in these diseases also rise some 
important questions to be answered: which cells are involved, is the regulation of FN 
by Notch in AML direct or indirect, what could be the role of Notch signaling in MDS, 
and which mechanism is regulating FN expression in MDS. Also in vitro assays using 
Notch pathways and/or FN inhibitors could provide us some clues about this. Also 
interesting, three-dimensional cultures of endothelial cells isolated from MDS and AML 
samples could be included in these studies.   
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Table S1. Clinical and laboratory characteristics of patients with MDS and AML  
   
PERIPHERAL BLOOD BM 
 
MDS 
AGE SEX 
ERITROCYTES 
(10^6/UL) 
LEUCOCYTES 
(10^3/UL) 
PLATELET 
(10^3µL) 
MYELOBLASTS 
(%) 
IPSS SCORE 
76 M 2.42 4.53 223 3.2 Low 
72 F 4.01 1.77 212 2.6 Low 
30 M 3.27 3.17 71 6.4 High 
67 F 4.09 2.34 45 5.0 Int-1 
73 M 3.54 2.5 136 12 Int-2 
40 F 3.17 2.56 257 4.7 Int-1 
60 M 1.93 2.9 22 1.8 Int-1 
34 F 3.6 5.02 64 3.0 Int-1 
67 F 2.59 1.4 272 1.6 Int-1 
71 M 2.96 3.91 29 0.6 Int-1 
58 F 3.03 7.86 57 0.3 Int-1 
 
AML 
AGE SEX BM MYELOBLASTS (%) 
36 F 75.4 
79 F 80.7 
64 M 23.0 
79 M 20.2 
68 M 26.8 
77 M 24.8 
75 M 21 
70 M 24 
82 M 24.0 
  
Table S2. PBS EDTA 2mM 
NaCl 137mM 8g 
Potassium dihydrogen phosphate (KH2PO4) 0,2g 
Sodium phosphate (Na2HPO4) 1,11g 
Potassium chloride (KCl) 0,2g 
EDTA 0,745g 
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Table S3. RQ-PCR primer sequences 
PRIMER SEQUENCE 5’ TO 3’ 
HUMAN 18S FWD GCCCTATCAACTTTCGATGGT 
HUMAN 18S RV CCGGAATCGAACCCTGATT 
HUMAN DLL4 FWD ACTACTGCACCCACCACTCC 
HUMAN DLL4 RV CCTGTCCACTTTCTTCTTCGC 
HUMAN HEY2 FWD TCGCCTCTCCACAACTTCAG 
HUMAN HEY2 RV TGAATCCGCATGGGCAAACG 
HUMAN HEY1 FWD GAAAGTTGCGCGTTATCTGAG 
HUMAN HEY1 RV GTTGAGATGCGAAACCAGTC 
HUMAN JAGGED1 FWD CGGCTTTGCCATGTGCTT 
HUMAN JAGGED1 RV TCTTCCTCCTCCATCCCTCTGTCA 
HUMAN FN FWD CAACAGTGGGAGCGGACCTA 
HUMAN FN RV CGGCTTCCTCCATAACAAGTACA 
 
Table S4. DNA loading buffer 
Glycerol 3ml 
Bromophenol blue 25mg 
H2O 10ml 
 
Table S5. 2% agarose gel 
0,5x TBE 100ml 
Agarose 2g (Heat  solution) 
Ethidium bromide 5µl 
 
Table S6. 5X TBE buffer 
Tris base 54g 
Boric acid  27,5g 
0.5 M EDTA 20ml (pH 8,0) 
H2O 980ml 
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SUPPLEMENTARY INFORMATION 
Table S7. 8% resolving gel 
H2O 2,3ml 
30% acrylamide mix 1,3ml 
1,5M Tris (pH8.8) 1,3ml 
10% SDS 0,05ml 
Ammonium persulfate 0,05ml 
TEMED 0,006ml 
 
Table S8. Stacking gel  
H2O 1,15ml 
30% acrylamide mix 0,33ml 
1,0M Tris (pH6.8) 0,500ml 
10% SDS 0,02ml 
Ammonium persulfate 0,02ml 
TEMED 0,004ml 
 
Table S9. Protein loading buffer  
500mM Tris-base 2ml 
Bromophenol blue 4ml 
Glycerol 2ml 
10% SDS 0,2g 
 
Table S10. Transfer buffer  
25mM Tris-base 15g 
193mM  Glycine 75g 
100% methanol 1l 
10% SDS 5ml 
H20 4l 
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SUPPLEMENTARY INFORMATION 
 
Table S11. 10x TBS and 1x TBS-Tween 
10X TBS 
Trizma HCl 24,23g 
NaCl 80,06g 
H20 1l (Adjust pH to 7,6) 
 
 
1X TBS-TWEEN 
TBS 10x 100ml 
H2O 900ml 
Tween20 1ml 
 
 
Table S12. 1x PBS 
 
NaCl 137mM 8g 
Potassium dihydrogen phosphate (KH2PO4) 0,2g 
Sodium phosphate (Na2HPO4) 1,11g 
Potassium chloride (KCl) 0,2g 
H2O 1l (Adjust pH to 7,2-7,4) 
 
Table S13. 10% polyacrylamide gel with gelatin 
H2O 3ml 
30% acrylamide mix 3,33ml 
1.0M Tris (pH8.8) 2,5ml 
1,2% Gelatin  1ml 
10% SDS 0,05ml 
Ammonium persulfate 0,033ml 
TEMED 0,012ml 
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Table S14. 2,5% Triton X-100 
Triton X-100 100ml 
dH20 3,9l 
 
Table S15: 10x and 1x low salt collagenase buffer  
10X LOW SALT COLLAGENASE BUFFER 
25mM Tris-base 60,6g 
NaCl 117g 
CaCl2 5,5g 
dH20 900ml 
dH20 Adjust to 1l (Adjust pH to 7,6) 
 
1X LOW SALT COLLAGENASE BUFFER 
10x low salt stock collagenase buffer 100ml 
dH20 900ml 
Brij-35 (30% w/v. Sigma) 670µl 
 
 
Table S16. Coomassie brilliant blue stock solution 
Methanol 500ml 
Coomassie brilliant blue 5ml 
H2O 400ml 
Acetic acid 100ml 
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Table S17. Destain solution 
Glacial acetic acid 200ml 
methanol 600ml 
H2O 1200ml 
 
Table S18. Coomassie brilliant blue working solution 
Coomassie brilliant blue stock solution 30ml 
Destain solution 70ml 
 
 
 
 
